Longevity

Abstract

While observational studies and small pilot trials suggest that vitamin D, omega-3 and exercise may slow biological aging, larger clinical trials testing these treatments individually or in combination are lacking. Here, we report the results of a post hoc analysis among 777 participants of the DO-HEALTH trial on the effect of vitamin D (2,000 IU per day) and/or omega-3 (1 g per day) and/or a home exercise program on four next-generation DNA methylation (DNAm) measures of biological aging (PhenoAge, GrimAge, GrimAge2 and DunedinPACE) over 3 years. Omega-3 alone slowed the DNAm clocks PhenoAge, GrimAge2 and DunedinPACE, and all three treatments had additive benefits on PhenoAge. Overall, from baseline to year 3, standardized effects ranged from 0.16 to 0.32 units (2.9–3.8 months). In summary, our trial indicates a small protective effect of omega-3 treatment on slowing biological aging over 3 years across several clocks, with an additive protective effect of omega-3, vitamin D and exercise based on PhenoAge.

Exploring the Latest Supplements, Vitamins, and Medications in Sinclair's Longevity Regimen

Maybe, maybe not. More research is needed.

Through metabolic screening, we identified uridine as a potential regulator to rejuvenate aged HSPCs.

Here we examined whether IL-11, a pro-inflammatory cytokine of the IL-6 family, has a negative effect on age-associated disease and lifespan.

Researchers publishing in Aging have found a molecule linking exercise to the inhibition of cellular senescence, one of the hallmarks of aging.

The researchers investigated whether NAD precusors, including nicotinamide and NR, along with the well-known compound rapamycin could rescue mitophagy, and they found positive results for all of these compounds.

TAC promoted tissue rejuvenation, including new neuron formation, and alleviated multiple aging hallmarks in aged mice, revealing the regenerative potential of adult tissues through physiological TERT activation.

The authors elaborate on the potential mechanisms underlying the connection between oral microbial dysbiosis and cognitive function impairment.

16α-hydroxyestriol was the star of this study, producing a 15% increase in median lifespan in male mice. However, it lowered median lifespan in females by 7%. While many drugs affect lifespan sex-specifically, opposing effects are rare; in fact, this is the first case in ITP’s history. Interestingly, we have another example from the same study: canagliflozin, when started at 16 months of age, led to a 14% increase in median lifespan in males and a 6% decline in females. In a previous ITP study, when started at 6 months, canagliflozin increased male lifespan without affecting female lifespan. All other tested drugs did not have a statistically significant effect on lifespan in either sex.